AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27473135 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/d oral conjugated equine estrogens (CEE)
Number of subjects: 95
Study 27473135 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg/d transdermal 17β‐estradiol
Number of subjects: 95
Study 27473135 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills and patch
Number of subjects: 95
Study 24439440 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin
Number of subjects: 323
Study 24439440 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 323
Study 24439440 — intervention group
Group type: COMPARATOR
Intervention: Comparison to previous studies
Number of subjects: 323
Study 23410710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior measured by accelerometry (≤100 counts per minute during wear-time)
Number of subjects: 0
Study 23410710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior measured by accelerometry
Number of subjects: 0
Study 20026378 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training + creatine supplementation (RT+CR)
Number of subjects: 27
Study 20026378 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training + placebo (RT+PL)
Number of subjects: 27
Study 20026378 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (CON)
Number of subjects: 27
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 386
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 386
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 386
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 386
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 386
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 386
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-dosed latanoprost/timolol fixed combination
Number of subjects: 386
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 386
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-dosed latanoprost
Number of subjects: 386
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-dosed travoprost
Number of subjects: 386
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 386
Study 18082886 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 386
Study 16476431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hansson hook-pins
Number of subjects: 199
Study 16476431 — intervention group
Group type: COMPARATOR
Intervention: AO-screws
Number of subjects: 199
Study 16476431 — intervention group
Group type: EXPERIMENTAL
Intervention: Undisplaced fractures
Number of subjects: 199
Study 16476431 — intervention group
Group type: COMPARATOR
Intervention: Displaced fractures
Number of subjects: 199
Study 12933423 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% (n = 20)
Number of subjects: 60
Study 12933423 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.5% (n = 20)
Number of subjects: 60
Study 12933423 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25% (n = 20)
Number of subjects: 60
Study 11226091 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg/kg IV preoperatively
Number of subjects: 110
Study 11226091 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 110
Study 9166095 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine
Number of subjects: 0
Study 9166095 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 0
Study 9166095 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) in 5-FU-refractory patients
Number of subjects: 0
Study 7682052 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 472
Study 7682052 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative surgery
Number of subjects: 472
Study 2419019 — intervention group
Group type: EXPERIMENTAL
Intervention: inosine pranobex (INPX) 3 g/day
Number of subjects: 61
Study 2419019 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 61
Study 30992012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport for LIFE: All Island (SFL:AI) physical activity programme for 12 weeks
Number of subjects: 740
Study 30992012 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 740
Study 28552331 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback therapy (NFT) for 20 sessions over four weeks
Number of subjects: 17
Study 28552331 — intervention group
Group type: COMPARATOR
Intervention: Control group participated in the same NF sessions from the fifth week to eighth week
Number of subjects: 17
Study 25837528 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (0.3 mg/kg)
Number of subjects: 156
Study 25837528 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (12 μg/kg)
Number of subjects: 156
Study 23473438 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Counseling (VC)
Number of subjects: 56
Study 23473438 — intervention group
Group type: EXPERIMENTAL
Intervention: 2Tone Trainer (2TT)
Number of subjects: 56
Study 23473438 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 56
Study 21675332 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Over Inertia intervention
Number of subjects: 24
Study 21675332 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 24
Study 19887219 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early mobilization (VEM)
Number of subjects: 71
Study 19887219 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 71
Study 16722152 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli Nissle (Mutaflor)
Number of subjects: 39
Study 16722152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 14746588 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact diode TSCPC
Number of subjects: 60
Study 14746588 — intervention group
Group type: COMPARATOR
Intervention: Non-contact diode TSCPC
Number of subjects: 60
Study 11519238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse specialist home care (half of prenatal care at home)
Number of subjects: 173
Study 11519238 — intervention group
Group type: COMPARATOR
Intervention: Usual prenatal care
Number of subjects: 173
Study 9766410 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) administration at birth (6 mg/kg elemental magnesium)
Number of subjects: 49
Study 9766410 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 49
Study 7816872 — intervention group
Group type: COMPARATOR
Intervention: Active drug (15 mg males, 10 mg females)
Number of subjects: 57
Study 7816872 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal suppository (2.5 mg b.i.d. for 3 days)
Number of subjects: 57
Study 7816872 — intervention group
Group type: COMPARATOR
Intervention: Oral capsule (chronic dosing)
Number of subjects: 57
Study 7816872 — intervention group
Group type: COMPARATOR
Intervention: Inhalation (acute dosing)
Number of subjects: 57
Study 7816872 — intervention group
Group type: COMPARATOR
Intervention: Oral and sublingual routes (acute dosing)
Number of subjects: 57
Study 7816872 — intervention group
Group type: COMPARATOR
Intervention: Fasted and fed states (oral dose)
Number of subjects: 57
Study 3047526 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day dydrogesterone continuously
Number of subjects: 81
Study 3047526 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day dydrogesterone for the first 12 days of each month
Number of subjects: 81
Study 3047526 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg/day conjugated oestrogen continuously
Number of subjects: 81
Study 1378707 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural patient-controlled analgesia (EPI-PCA)
Number of subjects: 117
Study 1378707 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 117
Study 1002084 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 2
Study 1002084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 28005194 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 7.5% gel
Number of subjects: 0
Study 28005194 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 26134916 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide twice daily (BID)
Number of subjects: 0
Study 26134916 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine once daily (QD)
Number of subjects: 0
Study 23778768 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal (REC; knee flexion immediately followed by a knee extension exercise)
Number of subjects: 33
Study 23778768 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional (TRA; non-preload; a concentric knee extension exercise)
Number of subjects: 33
Study 23778768 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; no exercise)
Number of subjects: 33
Study 21649650 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based programme of physical exercise (week 1)
Number of subjects: 552
Study 21649650 — intervention group
Group type: COMPARATOR
Intervention: No programme (week 2)
Number of subjects: 552
Study 19706374 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CR, 4x5 g/day creatine monohydrate for 5 days)
Number of subjects: 16
Study 19706374 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CR)
Number of subjects: 16
Study 19706374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P, same dose of a dextrose‐ascorbic acid placebo)
Number of subjects: 16
Study 19706374 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 17087116 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen vaccine atomization inhalation (A group)
Number of subjects: 90
Study 17087116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual allergen vaccine (B group)
Number of subjects: 90
Study 17087116 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypodermic injection (C group)
Number of subjects: 90
Study 17087116 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 healthy subjects)
Number of subjects: 90
Study 15261880 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT imaging using [(99m)Tc]TRODAT-1
Number of subjects: 29
Study 15261880 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 29
Study 11396751 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine 0.5 ml/kg (group B)
Number of subjects: 30
Study 11396751 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 0.5 ml/kg with 50 microg/kg midazolam (group BM)
Number of subjects: 30
Study 10029389 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive closed drains
Number of subjects: 80
Study 10029389 — intervention group
Group type: COMPARATOR
Intervention: High‐vacuum systems
Number of subjects: 80
Study 8075014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial support (picture depicting the initial physical situation)
Number of subjects: 0
Study 8075014 — intervention group
Group type: COMPARATOR
Intervention: No pictorial support (control group not explicitly mentioned)
Number of subjects: 0
Study 3192861 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen inhalation challenge
Number of subjects: 14
Study 3192861 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (control challenge)
Number of subjects: 14
Study 29948281 — intervention group
Group type: EXPERIMENTAL
Intervention: GentleWave (GW) System
Number of subjects: 56
Study 29948281 — intervention group
Group type: COMPARATOR
Intervention: ProUltra PiezoFlow Active Ultrasonic System (PF)
Number of subjects: 56
Study 29948281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems (GW and PF)
Number of subjects: 56
Study 29121999 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment partner and psychoeducation intervention
Number of subjects: 77
Study 29121999 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders of clinic appointments
Number of subjects: 77
Study 29121999 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 77
Study 26253728 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels
Number of subjects: 3763
Study 26253728 — intervention group
Group type: EXPERIMENTAL
Intervention: AGE levels
Number of subjects: 3763
Study 26253728 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE and AGE levels
Number of subjects: 3763
Study 23129815 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery training (15 minutes of imagining normal gait movement embedded in 30 minutes of gait training, 45 minutes/day, 3 times/week)
Number of subjects: 28
Study 23129815 — intervention group
Group type: COMPARATOR
Intervention: Gait training only (30 minutes/day, 3 times/week)
Number of subjects: 28
Study 21161652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bursectomy
Number of subjects: 210
Study 21161652 — intervention group
Group type: COMPARATOR
Intervention: Nonbursectomy
Number of subjects: 210
Study 18458892 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 52
Study 18458892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir
Number of subjects: 52
Study 18458892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir
Number of subjects: 52
Study 16566675 — intervention group
Group type: EXPERIMENTAL
Intervention: COLD-fX (200 mg/capsule, 2 capsules/day)
Number of subjects: 43
Study 16566675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 16566675 — intervention group
Group type: EXPERIMENTAL
Intervention: COLD-fX
Number of subjects: 43
Study 14736353 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (8 minutes)
Number of subjects: 15
Study 14736353 — intervention group
Group type: COMPARATOR
Intervention: Stationary sitting astride a barrel (8 minutes)
Number of subjects: 15
Study 11571330 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (17.5 mg in the first week, 35.0 mg in the second and third weeks)
Number of subjects: 32
Study 11571330 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 32
Study 9590313 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 75
Study 9590313 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 75
Study 9590313 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol combined with Midazolam (Synergistic)
Number of subjects: 75
Study 7923961 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids or a combination of steroids and cytotoxic therapy
Number of subjects: 17
Study 7923961 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 17
Study 3392755 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Environmental Stimulation Therapy (REST) with anti-alcohol messages for 2.5 hours
Number of subjects: 2
Study 3392755 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Environmental Stimulation Therapy (REST) with revised anti-alcohol message for 2.5 hours
Number of subjects: 2
Study 3392755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no REST)
Number of subjects: 2
Study 30684078 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable endoscope (DE)
Number of subjects: 0
Study 30684078 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 0
Study 28095412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target SBP <125 mmHg)
Number of subjects: 83
Study 28095412 — intervention group
Group type: COMPARATOR
Intervention: Guideline blood pressure lowering (target SBP <140 mmHg)
Number of subjects: 83
Study 28095412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering (target LDL-cholesterol <1.3 mmol/l)
Number of subjects: 83
Study 28095412 — intervention group
Group type: COMPARATOR
Intervention: Guideline lipid lowering (target LDL-c <3.0 mmol/l)
Number of subjects: 83
Study 28095412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering therapy
Number of subjects: 83
Study 28095412 — intervention group
Group type: COMPARATOR
Intervention: Guideline lipid lowering therapy
Number of subjects: 83
Study 28095412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure and lipid lowering
Number of subjects: 83
Study 28095412 — intervention group
Group type: COMPARATOR
Intervention: Guideline blood pressure and lipid lowering
Number of subjects: 83
Study 26765631 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Exercise (ME)
Number of subjects: 71
Study 26765631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Exercise (CE)
Number of subjects: 71
Study 26765631 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 71
Study 23233551 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized lifestyle consultation
Number of subjects: 13016
Study 23233551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no individualized lifestyle consultation)
Number of subjects: 13016
Study 21492255 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg/day of liposomal amphotericin B for 5 days
Number of subjects: 35
Study 21492255 — intervention group
Group type: COMPARATOR
Intervention: 20 mgSbV/kg/day of N-methyl glucamine for 20 days
Number of subjects: 35
Study 19531744 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-hydroxymethylene diphosphonate (HDP) digital blood flow scintigraphy
Number of subjects: 57
Study 17573730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized cat dander extract
Number of subjects: 50
Study 17573730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15367188 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain (enamel matrix derivative) application
Number of subjects: 22
Study 15367188 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (no Emdogain application)
Number of subjects: 22
Study 11258087 — intervention group
Group type: EXPERIMENTAL
Intervention: Active, maxillary, flat‐plane, hard acrylic splint
Number of subjects: 63
Study 11258087 — intervention group
Group type: COMPARATOR
Intervention: Palatal splint that did not interfere with occlusion
Number of subjects: 63
Study 9568790 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol intervention
Number of subjects: 29133
Study 9568790 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum alpha-tocopherol, dietary vitamin E, or selenium
Number of subjects: 29133
Study 7628832 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.15 IU insulin/kg body weight) to induce hypoglycemia
Number of subjects: 10
Study 7628832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 10
Study 2699072 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (40 Gy) and cystectomy
Number of subjects: 107
Study 2699072 — intervention group
Group type: COMPARATOR
Intervention: Radical radiation therapy (60 Gy) and salvage cystectomy
Number of subjects: 107
Study 323663 — intervention group
Group type: EXPERIMENTAL
Intervention: tri-potassium di-citrato bismuthate (De-Nol)
Number of subjects: 46
Study 323663 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study 31790555 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD
Number of subjects: 1014
Study 31790555 — intervention group
Group type: COMPARATOR
Intervention: Referents
Number of subjects: 1014
Study 31676001 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV testing and counselling (HB-HTC) during two visits (one weekday and one weekend)
Number of subjects: 18286
Study 31676001 — intervention group
Group type: COMPARATOR
Intervention: First visit (weekday)
Number of subjects: 18286
Study 31676001 — intervention group
Group type: EXPERIMENTAL
Intervention: Second visit (weekend)
Number of subjects: 18286
Study 31676001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per person tested
Number of subjects: 18286
Study 28866338 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200mg/day
Number of subjects: 52
Study 28866338 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400mg/day
Number of subjects: 52
Study 28866338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 25879648 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-thawed maternal milk (MM)
Number of subjects: 140
Study 25879648 — intervention group
Group type: COMPARATOR
Intervention: Combined fresh and freeze-thawed maternal milk (MM)
Number of subjects: 140
Study 24331029 — intervention group
Group type: EXPERIMENTAL
Intervention: In utero percutaneous vesicoamniotic shunting (VAS)
Number of subjects: 31
Study 24331029 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 31
Study 21304241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg (half-dose)
Number of subjects: 91
Study 21304241 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg (standard-dose)
Number of subjects: 91
Study 19562371 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity indicators (watching television >1 hour on weekdays, club sports participation <1 time/week, sweetened drinks consumption ≥3 times/week, skipping breakfast)
Number of subjects: 1079
Study 19562371 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy, parental overweight, low parental education
Number of subjects: 1079
Study 19562371 — intervention group
Group type: EXPERIMENTAL
Intervention: Migration background
Number of subjects: 1079
Study 19562371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes targeting physical inactivity and dietary habits
Number of subjects: 1079